U.S. Spends an Estimated $7.9 Billion on Negative Breast and Prostate Cancer Tests; NuView Life Sciences Poised to Change Cancer Diagnosis and Treatment

Share Article

Traditional methods of diagnosing malignant cancer are invasive, expensive, and not always accurate. Now, a new way to identify cancer cells stands ready to change everything.

Paul Crowe, CEO Of NuView Life Sciences, discusses NVLS' plan to help cancer diagnostics.

The earlier we can detect cancer, the higher probability of successful treatment, and importantly, improved patient outcomes.

It’s estimated that the U.S. spends approximately $7.9 billion annually on negative prostate and breast cancer biopsies. Diagnosing and treating malignant cancer is an invasive and prohibitively expensive process. While there are currently a variety of diagnostic methods available,(1) many of these methods lack accuracy and specificity in diagnosing the nature, invasiveness or localization of the disease state. Current treatment protocols are highly invasive procedures. Biopsies are typically performed after a suspicious mammogram or an elevated PSA are observed by the physician, often causing a referral for a biopsy which are uncomfortable and drive up medical costs. Furthermore, these biopsies often result in diagnoses of benign cancers that may not require treatment.

Paul Crowe, Chairman and Chief Executive Officer of NuView Life Sciences, explained, “The earlier we can detect cancer, the higher probability of successful treatment, and importantly, improved patient outcomes. Our goal is to provide the healthcare industry with NuView’s state of the art technology in early non-invasive detection, NuView’s novel technology and application will expedite the identification and treatment of many types of malignant cancers rapidly. This technology will also help patients by reducing the stress and anxiety they feel while waiting for a confirmation of their cancer diagnosis. It will make the entire process faster and more accurate, and will help lower medical costs for both patients and third-party payers.”

Positron Emission Tomography (PET) scans have been used to diagnose different types of cancers since the 1970s, but there are limitations to their accuracy and reliability. The scans can be influenced by various internal and external factors, like metabolism, and it can take several hours to several days for traditional imaging agents to accumulate in cancer cells in levels great enough to be detected.(2) Moreover, some traditional imaging methods are not as accurate in locating certain types of cancer inside denser tissues, and smaller lesions may not be detected at all.(5) Nuview’s mission is to provide early detection, new application and improved quality of life for those affected through NuView’s personalized treatment characterization.

NuView’s research focuses on identifying a cancer cells over-expression of a unique class of receptors in malignant cells. NuView’s research team has identified a receptor family, Vasoactive Intestinal Peptide (VIP), a prevalent neuro-peptide with two subtype receptors, VPAC1 and VPAC2. By taking advantage of the known overexpression of VIP receptors on the surface of cancerous cells, and the ability to create a unique biomarker to bind a certain part of the receptor, NuView’s research team can now quantify rapid, non-invasive tests for early detection of many cancer forms. Importantly, Nuview’s non-invasive, in-vitro examination is also applicable to healthcare facilities that already have in use, Positron emission tomography–magnetic resonance imaging (PET-MRI).

Crowe said, “What does all this tell us? It tells us for the first time in cancer research and treatment we have a plan that focuses on patient quality of life. Beginning with a non-invasive test for cancer, followed by minimally evasive localization imagining (PET-MRI), and finally, NuView’s HTOB system will for the first time asses the lowest minimum treatment required to provide a high-quality of life for those affected.”

With all the money spent on negative tests for prostate and breast cancer, Crowe noted, “It doesn’t have to be this way. We’ve been able to successfully use NV-VPAC1 within urine (liquid biopsy) screening tests to identify malignant prostate genital urinary cancers. Our results have been accurate in diagnosing cancer in 100% of affected men, and no false positives were reported in healthy, normal men involved in our research. It’s an incredible result of which we’re particularly proud.”

Since research and testing using NuView’s exclusive imaging agent have already been so successful in clinical feasibility studies which have been published in peer-reviewed journals, the company now plans to begin Phase II clinical trials in 2017.

About NuView Life Sciences:

Founded in 2005, NuView Life Sciences is a biotechnology company located in Park City, Utah, working to reform the way cancer is diagnosed and treated in our modern healthcare system. NuView is focused on creating precision cancer diagnostics and therapeutics to improve patient outcomes while reducing healthcare costs through the development and clinical application of its exclusive peptide analog technology, NV-VPAC1.

Led by a team of industry experts with decades of combined experience in healthcare and medical imaging technologies, NuView is poised to change how we look for and respond to cancer. To learn more about NuView Life Sciences, please visit http://nuviewinfo.com/site/3/.

About Paul Crowe:

Paul Crowe is a veteran healthcare industry leader who has already helped develop several successful start-up and early-stage healthcare companies, bringing diagnostic ultrasound, nuclear magnetic resonance (NMR/MRI), mobile positron emission tomography (PET), and gamma knife radio surgery technology to market. He currently serves on the Board of Radio Surgical Centers of San Diego, located at Scripps Memorial Hospital.

Sources:
1.    Diagnostics. Cancer Treatment Centers of America. 2016.
2.    Positron Emission Tomography—Computed Tomography (PET/CT). RadiologyInfo.org For Patients. June 11, 2015.
3.    SEER Stat Fact Sheets: Prostate Cancer. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. 2016.
4.    New Nuclear-Imaging Tests Show Promise in Locating Cancer. The Wall Street Journal. September 25, 2016.
5.    Metabolic PET Imaging in Cancer Detection and Therapy Response. Seminars in Oncology.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Karla Jo Helms
JoTo PR
+1 (888) 202-4614 Ext: 802
Email >